Emergence of crohn's disease in juvenile idiopathic arthritis during treatment with etanercept: A causal link or a mere coincidence?

Journal of Gastrointestinal and Liver Diseases

Volumn 19, Issue 3, 2010, Pages 342-

  Oikonomou, Konstantinos A ^a   Kapsoritakis, Andreas N ^a   Tsiopoulos, Fotios D ^a   Tsikouras, Antonios N ^a   Potamianos, Spyros ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CASPASE 3; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ANKYLOSING SPONDYLITIS; APOPTOSIS; CASE REPORT; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG WITHDRAWAL; ENTERITIS; ENZYME ACTIVATION; FEMALE; FOLLOW UP; GENETIC LINKAGE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LAMINA PROPRIA; LETTER; MONONUCLEAR CELL; RECURRENT DISEASE; REMISSION; TREATMENT RESPONSE;

ADOLESCENT; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; RECEPTORS, TUMOR NECROSIS FACTOR; RECURRENCE; TREATMENT OUTCOME;

EID: 78650081862     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (8)

1. Haraoui B, Krelenbaum M. Emergence of Crohn's Disease During Treatment with the Anti-Tumor Necrosis Factor Agent Etanercept for Ankylosing Spondylitis: Possible Mechanisms of Action. Semin Arthritis Rheum 2009; 39: 176-81.
2. Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum 2003; 48: 1093-1101.
3. Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121: 1088-1094.
4. Braun J, Baraliakos X, Listing J, et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007; 57: 639-647.
5. Dallocchio A, Canioni D, Ruemmele F, et al; the SOFREMIP. Occurrence of inflammatory bowel disease during treatment of juvenile idiopathic arthritis with etanercept: a French retrospective study. Rheumatology (Oxford) 2010; May 14 (Epub ahead of print).
6. Cohen R, Robinson D Jr, Paramore C, Fraeman K, Renahan K, Bala M. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. Inflamm Bowel Dis 2008; 14: 738-743.
7. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab.Arthritis Rheum 2003; 48: 780-790.
8. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept.Ann Rheum Dis 2003; 62: 561-564.